Uterine Cancer - Pipeline Review, H1 2014 @ http://www.researchmoz.us/uterine-cancer-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Uterine Cancer - Pipeline Review, H1 2014
Uterine Cancer - Pipeline Review, H1 2014
Summary
Global Markets Directs, Uterine Cancer - Pipeline Review, H1 2014, provides an overview of the Uterine Cancers therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Uterine Cancer and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Uterine Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uterine Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and
industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uterine Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uterine Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 4
introduction 5
global Markets Direct Report Coverage 5
uterine Cancer Overview 6
therapeutics Development 7
pipeline Products For Uterine Cancer - Overview 7
pipeline Products For Uterine Cancer - Comparative Analysis 8
uterine Cancer - Therapeutics Under Development By Companies 9
uterine Cancer - Therapeutics Under Investigation By Universities/institutes 11
uterine Cancer - Pipeline Products Glance 12
late Stage Products 12
clinical Stage Products 13
Uterine Cancer - Pipeline Review, H1 2014

2. early Stage Products 14
uterine Cancer - Products Under Development By Companies 15
uterine Cancer - Products Under Investigation By Universities/institutes 16
uterine Cancer - Companies Involved In Therapeutics Development 17
azaya Therapeutics Incorporated 17
endoceutics, Inc. 18
sunshine Biopharma, Inc. 19
uterine Cancer - Therapeutics Assessment 20
assessment By Monotherapy Products 20
assessment By Target 21
assessment By Mechanism Of Action 24
assessment By Route Of Administration 27
assessment By Molecule Type 29
drug Profiles 31
acolbifene Hydrochloride - Drug Profile 31
product Description 31
mechanism Of Action 31
r&d Progress 31
angiotensin 1-7 - Drug Profile 32
product Description 32
mechanism Of Action 32
r&d Progress 32
docetaxel Liposomal - Drug Profile 34
product Description 34
mechanism Of Action 34
r&d Progress 34
adva-27a - Drug Profile 36
product Description 36
mechanism Of Action 36
r&d Progress 36
adva-32a - Drug Profile 38
product Description 38
mechanism Of Action 38
r&d Progress 38
compound-2 - Drug Profile 39
product Description 39
mechanism Of Action 39
r&d Progress 39
uterine Cancer - Recent Pipeline Updates 40
uterine Cancer - Dormant Projects 45
uterine Cancer - Product Development Milestones 46
featured News & Press Releases 46
aug 12, 2013: Advanomics Wins Research Grant For Cancer Drug Candidate 46
jun 19, 2013: Sunshine Biopharma's Anticancer Drug Candidate Adva-27a Is Unaffected By Recent Supreme Court Ruling On Patentability Of Human Genes 46
jan 15, 2013: Advanomics Files New Patent Application For Multidrug Resistance Adva-27a Anticancer Compound 46
dec 10, 2012: Sunshine Biopharma Completes Another Ind-enabling Study Of Adva-27a 47
jun 13, 2012: Azaya Therapeutics Reports Phase I Clinical Trial Results Of Ati-1123 47
appendix 49
methodology 49
coverage 49
secondary Research 49
primary Research 49
expert Panel Validation 49
contact Us 50
disclaimer 50
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Uterine Cancer - Pipeline Review, H1 2014

3. USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Uterine Cancer - Pipeline Review, H1 2014